D
David J. Hosking
Researcher at University of Nottingham
Publications - 134
Citations - 10711
David J. Hosking is an academic researcher from University of Nottingham. The author has contributed to research in topics: Osteoporosis & Bone remodeling. The author has an hindex of 48, co-authored 134 publications receiving 10354 citations. Previous affiliations of David J. Hosking include University of Texas Health Science Center at San Antonio & Nottingham City Hospital.
Papers
More filters
Journal ArticleDOI
Ten years' experience with alendronate for osteoporosis in postmenopausal women.
Henry G. Bone,David J. Hosking,Jean-Pierre Devogelaer,Joseph R. Tucci,Ronald Emkey,Richard P. Tonino,Jose Adolfo Rodriguez-Portales,Robert W. Downs,Jayanti Gupta,Arthur C. Santora,Uri A. Liberman +10 more
TL;DR: The therapeutic effects of alendronate were sustained, and the drug was well tolerated over a 10-year period, as measured by bone density and biochemical markers of bone remodeling.
Journal ArticleDOI
Ten Years’ Experience With Alendronate for Osteoporosis in Postmenopausal Women
Henry G. Bone,David J. Hosking,Jean-Pierre Devogelaer,Joseph R. Tucci,Ronald Emkey,Richard P. Tonino,Jose Adolfo Rodriguez-Portales,Robert W. Downs,Jayanti Gupta,Arthur C. Santora,Uri A. Liperman +10 more
TL;DR: The therapeutic effects of alendronate were sustained, and the drug was well tolerated over a 10-year period, and safety data did not suggest that prolonged treatment resulted in any loss of benefit.
Journal ArticleDOI
The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation.
P. Lips,David J. Hosking,Kurt Lippuner,J. M. Norquist,L. Wehren,G. Maalouf,S. Ragi-Eis,Julie Chandler +7 more
TL;DR: The prevalence of inadequacy amongst women with osteoporosis in different regions of the world has not been well characterized and the optimal serum 25(OH)D lies in the region of 50–80 nmol L−1 (20–32 ng mL−1).
Journal ArticleDOI
Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy
Stanley Wallach,S. Cohen,David M. Reid,R.A. Hughes,David J. Hosking,Roland Laan,S. M. Doherty,Michael Maricic,Clifford J. Rosen,Janet E. Brown,I P Barton,Chines Arkadi Aaron +11 more
TL;DR: Risedronate was efficacious in both men and women, irrespective of underlying disease and duration of corticosteroid therapy, and had a favorable safety profile, with a similar incidence of upper gastrointestinal adverse events in the placebo and active treatment groups.
Journal ArticleDOI
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
David J. Hosking,C. E. D. Chilvers,C. Christiansen,Pernille Ravn,R. D. Wasnich,Philip D. Ross,Michael R. McClung,Ana Balske,D. E. Thompson,M. Daley,A. J. Yates +10 more
TL;DR: Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear.